

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



Olotu, A; Lusingu, J; Leach, A; Lievens, M; Vekemans, J; Msham, S; Lang, T; Gould, J; Dubois, MC; Jongert, E; Vansadia, P; Carter, T; Njuguna, P; Awuondo, KO; Malabeja, A; Abdul, O; Gesase, S; Mturi, N; Drakeley, CJ; Savarese, B; Villafana, T; Lapierre, D; Ballou, WR; Cohen, J; Lemnge, MM; Peshu, N; Marsh, K; Riley, EM; von Seidlein, L; Bejon, P (2011) Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. *The Lancet infectious diseases*, 11 (2). pp. 102-109. ISSN 1473-3099 DOI: [https://doi.org/10.1016/S1473-3099\(10\)70262-0](https://doi.org/10.1016/S1473-3099(10)70262-0)

Downloaded from: <http://researchonline.lshtm.ac.uk/1107/>

DOI: [10.1016/S1473-3099\(10\)70262-0](https://doi.org/10.1016/S1473-3099(10)70262-0)

#### Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

## Supplementary webappendix

This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Olotu A, Lusingu J, Leach A, et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial . *Lancet Infect Dis* 2011; published online Jan 14. DOI:10.1016/S1473-3099(10)70262-0.


**Supplementary Figure 1 Legend**

Anti-CS titres with interpolated fit of log-transformed values (3=1000 EU/mL, 2=100 EU/mL, 1=10 EU/mL, 0=1 EU/mL). Time=0 is 1 month after the final vaccination.

**Supplementary Figure 2 Legend**

For each model, anti-CS titres were divided into two groups, above and below a dichotomization point (x axis) and goodness of fit for each model measured (log likelihood, y axis).

Supplementary figure 1: Individual anti-CS titres from the first 20 RTS,S/AS01E vaccinees



Supplementary figure 2: Goodness fit log likelihood and dichotomization point for anti-CS

